Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology at Northwestern University.
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy.
In two distinct studies, scientists show how synthetic biology can be used to address a challenging problem in cancer immunotherapy: the way immunotherapy-related approaches focused on the short-term killing of tumor cells could fail to eradicate tumors because tumor growth occurs on longer timescales.
After analyzing data from a public repository, CD4-T, CD8-T cells, and Treg cells, a team of researchers led by bioinformatics Mabel Vidal from the University of Concepcion and working with researchers from MELISA Institute and other academic institutions discovered a distinctive genetic signature among subsets of infiltrating T cells of various types of cancer.
A novel method of reprogramming the immune cells to shrink or destroy cancer cells has been demonstrated to work in melanoma, a difficult to treat and destructive skin cancer.
Researchers from Johns Hopkins Medicine claim to have successfully “slid” genetic instructions into a cell and produced essential proteins that were lacking from those cells using a cell’s normal process for creating proteins.
Mycobacterium tuberculosis (Mtb), the bacteria that causes tuberculosis (TB), continues to be a major infectious threat to global public health.
According to a recent study conducted by scientists at Emory University in Atlanta, the administration of broad-spectrum antibiotics in mice with malignant melanoma, an aggressive type of skin cancer, expedited their metastatic bone growth.
A minimally invasive technique was created and improved by scientists at Terasaki Institute for Biomedical Innovation (TIBI) to develop immunotherapeutic cancer treatments.
A discovery regarding how a particular protein is triggered in tumor cells, conducted by researchers at the University of California, Irvine, may lead to more effective therapies for some of the deadliest types of cancer.
Cancer cells can have thousands of mutations in their DNA. However, only a handful of those actually drive the progression of cancer; the rest are just along for the ride.
The University of Texas MD Anderson Cancer Center scientists have created an ultrasound-guided cancer immunotherapy approach that promotes systemic antitumor immunity and increases immune checkpoint blockade therapeutic potential. Nature Nanotechnology published the results of the pioneering study.
In cancer management, biomarkers are commonly used to guide treatment decisions and evaluate patient outcomes.
Researchers at Emory University have uncovered a mechanism for skin cell death that might lead to novel therapies for “flesh-eating” infections, alopecia, hives, and possibly even melanoma, the deadliest type of skin cancer.
Many cancer patients have benefited from the development of anti-cancer immunotherapy drugs known as immune checkpoint inhibitors, but patients with mucosal melanomas—melanomas that occur in the mucous membranes of the head, neck, eyes, respiratory system, and genitourinary region rather than on the skin—are highly resistive to immune checkpoint inhibitors for reasons researchers do not fully understand.
Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson Cancer Center have discovered that vitamin E can enhance immunotherapy responses by stimulating the activity of dendritic cells in the tumor.
Melanoma is a somewhat unusual cancer-;one that blooms before our very eyes, often on sun-exposed skin, and can quickly become deadly as it turns our own skin against us and spreads to other organs.
Natural killer (NK) cells, which are part of the body’s innate, or first-line, immune response, interact with tumor cells, viral infections, and solid organ transplants, according to a new study.
Researchers at the University of Michigan Rogel Cancer Center found that a cytokine, a category of protein that acts as messengers in the body, and a fatty acid can work together to trigger a type of cell death previously defined by studies with synthetic molecules.